Evidence map›Paper›PMID 28507654›Full record

ArticleCanadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC

Cost-effectiveness of pharmacist care for managing hypertension in Canada.

Carlo Marra, Karissa Johnston, Valerie Santschi, Ross T Tsuyuki

Abstract read
In one paragraph

Article in Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. RBMJ open · 2021
    Trial
  5. A model-based cost-effectiveness analysis of prescribing by dietitians and therapeutic radiographers in England.The European journal of health economics : HEPAC : health economics in prevention and care · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Expanding team-based care for hypertension and cardiovascular risk management with HEARTS in the Americas.Revista panamericana de salud publica = Pan American journal of public health · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Carlo MarraSchool of Pharmacy (Marra), University of Otago, New Zealand; Broadstreet Health Economics & Outcomes Research (Johnston), Vancouver, BC; the School of Nursing Sciences (Santschi), University of Applied Sciences Western Switzerland, Switzerland; and Faculty of Medicine and Dentistry (Tsuyuki), University of Alberta, Edmonton, Alberta.
Karissa JohnstonSchool of Pharmacy (Marra), University of Otago, New Zealand; Broadstreet Health Economics & Outcomes Research (Johnston), Vancouver, BC; the School of Nursing Sciences (Santschi), University of Applied Sciences Western Switzerland, Switzerland; and Faculty of Medicine and Dentistry (Tsuyuki), University of Alberta, Edmonton, Alberta.
Valerie SantschiSchool of Pharmacy (Marra), University of Otago, New Zealand; Broadstreet Health Economics & Outcomes Research (Johnston), Vancouver, BC; the School of Nursing Sciences (Santschi), University of Applied Sciences Western Switzerland, Switzerland; and Faculty of Medicine and Dentistry (Tsuyuki), University of Alberta, Edmonton, Alberta.
Ross T TsuyukiSchool of Pharmacy (Marra), University of Otago, New Zealand; Broadstreet Health Economics & Outcomes Research (Johnston), Vancouver, BC; the School of Nursing Sciences (Santschi), University of Applied Sciences Western Switzerland, Switzerland; and Faculty of Medicine and Dentistry (Tsuyuki), University of Alberta, Edmonton, Alberta.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMore than half of all heart disease and stroke are attributable to hypertension, which is associated with approximately 10% of direct medical costs globally. Clinical trial evidence has demonstrated that the benefits of pharmacist intervention, including education, consultation and/or prescribing, can help to reduce blood pressure; a recent Canadian trial found an 18.3 mmHg reduction in systolic blood pressure associated with pharmacist care and prescribing. The objective of this study was to evaluate the economic impact of such an intervention in a Canadian setting.

methodsA Markov cost-effectiveness model was developed to extrapolate potential differences in long-term cardiovascular and renal disease outcomes, using Framingham risk equations and other published risk equations. A range of values for systolic blood pressure reduction was considered (7.6-18.3 mmHg) to reflect the range of potential interventions and available evidence. The model incorporated health outcomes, costs and quality of life to estimate an overall incremental cost-effectiveness ratio. Costs considered included direct medical costs as well as the costs associated with implementing the pharmacist intervention strategy.

resultsFor a systolic blood pressure reduction of 18.3 mmHg, the estimated impact is 0.21 fewer cardiovascular events per person and, discounted at 5% per year, 0.3 additional life-years, 0.4 additional quality-adjusted life-years and $6,364 cost savings over a lifetime. Thus, the intervention is economically dominant, being both more effective and cost-saving relative to usual care. DISCUSSION: Across a range of one-way and probabilistic sensitivity analyses of key parameters and assumptions, pharmacist intervention remained both effective and cost-saving.

conclusionComprehensive pharmacist care of hypertension, including patient education and prescribing, has the potential to offer both health benefits and cost savings to Canadians and, as such, has important public health implications.

Identifiers

PMID28507654
PMCPMC5415065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.